u/h3xpl01t

Author argues Samsung Biologics' $2.18B acquisition of PolyPeptide Group validates the peptide and GLP-1 market, and RMTG is already operating in that same sector through Cellgenic and ISSCA. Q2 revenue of $4.02M was up 309% YoY with 64% gross margins and $565k operating income, which the author believes makes the debt manageable via real cash flow rather than dilution. The stated catalyst is Q3 revenue around $8M over the next few months, which the author expects to draw attention to the fundamentals. Main risk is the scary debt on the balance sheet, though the author argues profitability changes the dynamic.